These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16416231)

  • 21. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.
    Fréling E; Baumann C; Cuny JF; Bigard MA; Schmutz JL; Barbaud A; Peyrin-Biroulet L
    Am J Gastroenterol; 2015 Aug; 110(8):1186-96. PubMed ID: 26195181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy.
    Farkas K; Lakatos PL; Nagy F; Szepes Z; Miheller P; Papp M; Palatka K; Bálint A; Bor R; Wittmann T; Molnár T
    Scand J Gastroenterol; 2013 Dec; 48(12):1394-8. PubMed ID: 24131338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study.
    Felder JB; Korelitz BI; Rajapakse R; Schwarz S; Horatagis AP; Gleim G
    Am J Gastroenterol; 2000 Aug; 95(8):1949-54. PubMed ID: 10950041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?
    Molander P; Färkkilä M; Ristimäki A; Salminen K; Kemppainen H; Blomster T; Koskela R; Jussila A; Rautiainen H; Nissinen M; Haapamäki J; Arkkila P; Nieminen U; Kuisma J; Punkkinen J; Kolho KL; Mustonen H; Sipponen T
    J Crohns Colitis; 2015 Jan; 9(1):33-40. PubMed ID: 25052347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: A retrospective study.
    Chauvin A; Le Thuaut A; Belhassan M; Le Baleur Y; Mesli F; Bastuji-Garin S; Delchier JC; Amiot A
    Dig Liver Dis; 2014 Aug; 46(8):695-700. PubMed ID: 24893686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study.
    Steenholdt C; Molazahi A; Ainsworth MA; Brynskov J; Østergaard Thomsen O; Seidelin JB
    Scand J Gastroenterol; 2012 May; 47(5):518-27. PubMed ID: 22375898
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease.
    Kim PS; Zlatanic J; Korelitz BI; Gleim GW
    Am J Gastroenterol; 1999 Nov; 94(11):3254-7. PubMed ID: 10566725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
    Warman A; Straathof JW; Derijks LJ
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Relapse rates of ulcerative colitis in remission and factors related to relapse].
    Park BJ; Lee KJ; Hwang JC; Sin SJ; Chung JY; Cho SW
    Korean J Gastroenterol; 2008 Jul; 52(1):21-6. PubMed ID: 19077487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors for small bowel bleeding in chronic nonsteroidal anti-inflammatory drug users.
    Cho KM; Park SY; Chung JO; Jun CH; Kim TJ; Son DJ; Kim BS; Park CH; Kim HS; Choi SK; Rew JS
    J Dig Dis; 2015 Sep; 16(9):499-504. PubMed ID: 26147360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inflammatory cytokine gene polymorphisms, nonsteroidal anti-inflammatory drug use, and risk of adenoma polyp recurrence in the polyp prevention trial.
    Sansbury LB; Bergen AW; Wanke KL; Yu B; Caporaso NE; Chatterjee N; Ratnasinghe L; Schatzkin A; Lehman TA; Kalidindi A; Modali R; Lanza E
    Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):494-501. PubMed ID: 16537707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Incidence of inflammatory bowel diseases in the department of Puy-de-Dôme in 1993 and 1994. EPIMICI. Epidémiologie des Maladies Inflammatoires Cryptogenetiques de l'Intestin group].
    Flamenbaum M; Zénut M; Aublet-Cuvelier B; Larpent JL; Fabre P; Abergel A; Dapoigny M; Bommelaer G
    Gastroenterol Clin Biol; 1997; 21(6-7):491-6. PubMed ID: 9295977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Importance of Patients' Knowledge of Their Prescribed Medication in Improving Treatment Adherence in Inflammatory Bowel Disease.
    Tae CH; Jung SA; Moon HS; Seo JA; Song HK; Moon CM; Kim SE; Shim KN; Jung HK
    J Clin Gastroenterol; 2016 Feb; 50(2):157-62. PubMed ID: 26501880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
    Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.
    Mooiweer E; Severs M; Schipper ME; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
    J Crohns Colitis; 2015 Jan; 9(1):50-5. PubMed ID: 25518048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of nonsteroidal anti-inflammatory drugs on the use of gastroprotective medication in people with arthritis.
    Lapane KL; Spooner JJ; Pettitt D
    Am J Manag Care; 2001 Apr; 7(4):402-8. PubMed ID: 11310194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Incidence of inflammatory bowel diseases in Bretagne (1994-1995). ABERMAD. Association Bertonne d'Etude et de Recherche des Maladies de l'Appareil Digesif].
    Pagenault M; Tron I; Alexandre JL; Cruchant E; Dabadie A; Chaperon J; Robaszkiewicz M; Bretagne JF
    Gastroenterol Clin Biol; 1997; 21(6-7):483-90. PubMed ID: 9295976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Usefulness of non-steroid antiinflammatory drugs in patients with ulcerative colitis].
    Zwolińska-Wcisło M; Ptak-Belowska A; Targosz A; Urbańczyk K; Rozpondek P; Galicka-Latała D; Mach T
    Przegl Lek; 2009; 66(9):503-7. PubMed ID: 21033410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of Nonsteroidal Anti-Inflammatory Drugs and Risk of Chronic Kidney Disease in Subjects With Hypertension: Nationwide Longitudinal Cohort Study.
    Hsu CC; Wang H; Hsu YH; Chuang SY; Huang YW; Chang YK; Liu JS; Hsiung CA; Tsai HJ
    Hypertension; 2015 Sep; 66(3):524-33. PubMed ID: 26169048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.